{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-22-000008","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2022-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.212692+00:00","generated_at":"2026-06-27T06:14:22.489048+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcutis reports Q4 2021 net loss of $71.3M, cash $388.6M; FDA accepted NDA for roflumilast cream","bullets":["Net loss of $71.3M ($1.42 per share) for Q4 2021 vs $34.0M ($0.79) in Q4 2020.","Cash, equivalents and marketable securities $388.6M as of Dec 31, 2021; runway extended into 2024.","FDA accepted NDA for roflumilast cream in plaque psoriasis with PDUFA date July 29, 2022.","Completed enrollment of Phase 3 trial for roflumilast foam in seborrheic dermatitis; topline data mid-2022.","Secured $225M non-dilutive loan facility from SLR Capital Partners in December 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-22-000008","json":"https://secwatch.observer/filing/0001787306-22-000008.json","markdown":"https://secwatch.observer/filing/0001787306-22-000008.md","text":"https://secwatch.observer/filing/0001787306-22-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730622000008/0001787306-22-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730622000008/arqt-20220222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T06:14:22.489048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}